Andere Sprachen Orchestra BioMed Holdings, Inc.

Aktien

A3D6DV

US68572M1062

OBIO

Realtime-Estimate Cboe BZX Andere Börsenplätze 15:30:09 22.05.2024			% 5 Tage	% 1. Jan.
5,065 ^USD	-1,27 %		-1,35 %	-43,81 %

13.05.	Orchestra BioMed Holdings, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
30.04.	Orchestra BioMed Holdings, Inc. gibt bekannt, dass die AVIM-Therapie weltweit 110 erteilte Patente erreicht hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference	14:44
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000	13.05.
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update	13.05.
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	30.04.
Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	30.04.
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	30.04.
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	30.04.
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	27.03.
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors	26.03.
Orchestra BioMed Holdings, Inc. Announces Appointment of David Pacitti to Board of Directors	26.03.
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13.03.
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13.03.
Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13.03.
Orchestra BioMed to Participate in Upcoming Investor Conferences	07.03.
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients	06.03.
Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients	06.03.
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	26.02.
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Orchestra BioMed Holdings, Inc.

Aktien

A3D6DV

US68572M1062

OBIO

Andere Sprachen

Filter